ATE333287T1 - Prophylaxe und behandlung von autoimmunen entmyelinisierungserkrankungen durch fas- antagonisten - Google Patents

Prophylaxe und behandlung von autoimmunen entmyelinisierungserkrankungen durch fas- antagonisten

Info

Publication number
ATE333287T1
ATE333287T1 AT99922536T AT99922536T ATE333287T1 AT E333287 T1 ATE333287 T1 AT E333287T1 AT 99922536 T AT99922536 T AT 99922536T AT 99922536 T AT99922536 T AT 99922536T AT E333287 T1 ATE333287 T1 AT E333287T1
Authority
AT
Austria
Prior art keywords
prophylaxis
treatment
demyelinating diseases
autoimmune demyelinating
fas
Prior art date
Application number
AT99922536T
Other languages
English (en)
Inventor
Takehiro Yatomi
Original Assignee
Mochida Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mochida Pharm Co Ltd filed Critical Mochida Pharm Co Ltd
Application granted granted Critical
Publication of ATE333287T1 publication Critical patent/ATE333287T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT99922536T 1998-05-29 1999-05-28 Prophylaxe und behandlung von autoimmunen entmyelinisierungserkrankungen durch fas- antagonisten ATE333287T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP14953098 1998-05-29

Publications (1)

Publication Number Publication Date
ATE333287T1 true ATE333287T1 (de) 2006-08-15

Family

ID=15477161

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99922536T ATE333287T1 (de) 1998-05-29 1999-05-28 Prophylaxe und behandlung von autoimmunen entmyelinisierungserkrankungen durch fas- antagonisten

Country Status (6)

Country Link
US (1) US6759041B1 (de)
EP (1) EP1082967B1 (de)
AT (1) ATE333287T1 (de)
CA (1) CA2333880A1 (de)
DE (1) DE69932434D1 (de)
WO (1) WO1999062554A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19959049A1 (de) * 1999-12-07 2001-06-28 Deutsches Krebsforsch Kombination von Verbindungen, welche die biologischen Wirkungen von TNF-alpha und CD95L hemmen
US7848848B2 (en) * 2006-04-28 2010-12-07 Freeslate, Inc. Robotic station for capturing both image and weight of a sample
US8771689B2 (en) 2006-12-11 2014-07-08 The Board Of Trustees Of The Leland Stanford Junior University Alpha B-crystallin as a therapy for ischemia or inflammation
JP2010512403A (ja) * 2006-12-11 2010-04-22 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 炎症の治療法としてのαＢクリスタリン

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63230629A (ja) 1987-03-19 1988-09-27 Microbial Chem Res Found 自己免疫疾患予防治療剤
EP0723556A4 (de) 1993-10-14 2003-03-19 Immunex Corp Fas antagonisten und ihre verwendungen
US5830469A (en) * 1993-10-14 1998-11-03 Immunex Corporation Fas antagonists and uses thereof
JPH08127594A (ja) * 1993-11-10 1996-05-21 Mochida Pharmaceut Co Ltd Ｆａｓ抗原に結合する新規蛋白質およびそれをコードするＤＮＡ
IL114615A0 (en) * 1995-07-16 1995-11-27 Yeda Res & Dev Modulators of the function of fas receptors and other proteins
JP3925663B2 (ja) * 1995-06-30 2007-06-06 持田製薬株式会社 抗Ｆａｓリガンド抗体および該抗体を用いた測定法
US6399327B1 (en) * 1995-07-16 2002-06-04 Yeda Research And Development Co. Ltd. Modulators of the function of FAS receptors and other proteins
AU2527397A (en) * 1996-03-13 1997-10-01 Protein Design Labs, Inc. Fas ligand fusion proteins and their uses
WO1997042319A1 (en) 1996-05-02 1997-11-13 Mochida Pharmaceutical Co., Ltd. NOVEL Fas ANTIGEN DERIVATIVES
WO1998010070A1 (en) 1996-09-02 1998-03-12 Sumitomo Electric Industries, Ltd. HUMANIZED IMMUNOGLOBULIN REACTING SPECIFICALLY WITH Fas LIGAND OR ACTIVE FRAGMENTS THEREOF AND REGION INDUCING APOPTOSIS ORIGINATING IN Fas LIGAND
ATE273713T1 (de) 1996-10-31 2004-09-15 Mochida Pharm Co Ltd Fas-antagonist für die prophylaxe oder therapie von gvhd
US6544523B1 (en) * 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US6358508B1 (en) * 1997-06-11 2002-03-19 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor TR9
JP4439111B2 (ja) * 1997-10-10 2010-03-24 サイトビア インコーポレイテッド ジペプチドのアポトーシスインヒビターおよびそれらの使用
US6184210B1 (en) * 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
US6098631A (en) * 1998-01-21 2000-08-08 The Regents Of The University Of Michigan Compositions and methods for treating autoimmune disease

Also Published As

Publication number Publication date
DE69932434D1 (de) 2006-08-31
US6759041B1 (en) 2004-07-06
WO1999062554A1 (fr) 1999-12-09
EP1082967A4 (de) 2001-11-07
EP1082967B1 (de) 2006-07-19
CA2333880A1 (en) 1999-12-09
EP1082967A1 (de) 2001-03-14

Similar Documents

Publication Publication Date Title
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
DE60133029D1 (de) Mittel zur prävention oder behandlung von psoriasi
ATE334668T1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
ATE247117T1 (de) Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung von sexualfunktionsstörungen
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
ATE201138T1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung und prophylaxe der multiplen sclerose
ATE230757T1 (de) Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
PT705100E (pt) Guanidinas substituidas terapeuticas
DE69034148D1 (de) Kombinationstherapie zur Prophylaxe und/oder Behandlung von gutartiger prostatischer Hyperplasie
ATE179892T1 (de) Verwendung von lipid-gebundener glykoaminoglykanen zur behandlung der rheumatoider arthritis
DE60123238D1 (de) Zusammensetzungen zur behandlung von autoimmunkrankheiten
DE69427344D1 (de) Verabreichung von riluzol zur behandlung von neuro-aids
MX9704037A (es) 1,1-dioxidos de 1,2,5-tiadiazolidin-3-ona 2-substituida y composiciones y metodo de uso de los mismos.
DK0679393T3 (da) Pharmaceutisk præparat til behandling af osteoporose indeholdende xanthohumol
DE69814444D1 (de) Kombination von angiotensing-convertin-enzyme hemmern mit diuretikum zur behandlung von störungen der mikrozirkulation
ATE469907T1 (de) Triptolid-analoga zur behandlung von autoimmunkranheiten und entzündungen
DE69918972D1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
DE69405919D1 (de) Zusammensetzungen zur Behandlung von Keratinfasern
DE69227696D1 (de) Zusammensetzungen zur behandlung von hiv-infektionen
DE3854121D1 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
DE69420229D1 (de) Pharmazeutische Zusammensetzung zur Behandlung von AIDS
EA200000242A1 (ru) Применение фанхинона для лечения болезни альцгеймера
DE69913380D1 (de) Zusammensetzung zur behandlung von periodontalen erkrankungen
DE69932434D1 (de) Prophylaxe und Behandlung von autoimmunen Entmyelinisierungserkrankungen durch Fas-antagonisten
DE3679781D1 (de) Verwendung von zusammensetzungen fuer die behandlung und die prophylaxe von epithelialer zerstoerung.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties